HealthcareAug 10, 2026

Seagen Inc.

Company Profile Analysis

Book Demo Subscribe Now

Year Founded & Workforce

1996-12-31

2,700 Employees

Industry

Healthcare

Services

Seagen Inc. Overview

Company Headquarters: Washington, US

Founded: 1997

Workforce: ~ 2,700

Company Working: Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. It offers antibody-drug conjugates (ADCs), including Padcevtm (enfortumab vedotin-ejfv), which is used to treat metastatic urothelial cancers, Adcetris (brentuximab vedotin), which is used to treat Hodgkin's lymphoma, T-cell lymphomas, and CD30-expressing lymphomas. (Tucat) Tukysa. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Additionally, Seagen also licenses its antibody-drug conjugate technology to several biotechnology and pharmaceutical companies. Seagen serves customers on a global scale.

Strategy

The goal of Seagen Inc. is to discover, develop, and market cutting-edge cancer therapies that will greatly enhance people's quality of life. The company is also focused on expanding its market globally through the acquisition of small companies and alliances with important actors. In addition, the aim of Seagen Inc. is to become a preeminent global oncology company that develops and markets therapies specifically for cancer. Furthermore, it is also focused on expanding its product portfolio through R&D investments.

Company Snapshot

$916,713M

Revenue

2,700

Employees

1996-12-31

Founded

Washington, US

Headquarters

Key Developments

Date	Approach	Development
September 2021	Product Approval	The FDA has approved Seagen Inc’s TIVDAK (Tisotumab vedotin). It is used to treat cervical cancer that is recurrent or metastatic and esophageal squamous cell carcinoma cancer. It is also used in women whose cancer got worse during or after treatment with chemotherapy

Product Offering

Seagen Inc.
- Esophageal squamous cell carcinoma

Financial Performance

A plan for every need

Forecast+

Get unlimited access to forecasts, charts, and company data across every research report on Wantstats.

USD200/mo

About the Author

Wantstats Research Team

Wantstats' research desk profiles Seagen Inc. as part of our ongoing coverage of the Healthcare sector, drawing on public company data, filings, and market intelligence.

Powering the world's best teams.
From next-gen startups to established enterprises.

See our work in action

Start your data driven journey with us!

Book a Demo Now

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Seagen Inc.

Company Headquarters: Washington, US Founded: 1997 Workforce: ~ 2,700 Company Working: Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. It offers antibody-drug conjugates (ADCs), including Padcevtm (enfortumab vedotin-ejfv), which is used to treat metastatic urothelial cancers, Adcetris (brentuximab vedotin), which is used to treat Hodgkin's lymphoma, T-cell lymphomas, and CD30-expressing lymphomas. (Tucat) Tukysa. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Additionally, Seagen also licenses its antibody-drug conjugate technology to several biotechnology and pharmaceutical companies. Seagen serves customers on a global scale.

Starting from

$4,950